Breaking the Crosstalk of the Cellular Tumorigenic Network in NSCLC by a Highly Effective Drug Combination
D. Guergen, T. Conrad, M. Becker, S. Sebens, C. Roecken, J. Hoffmann, S. Langhammer
This study shows a low-dose drug combination effectively suppresses NSCLC PDX tumors with high response and complete remission rates.
bioRxiv · Oct 23, 2021 · PreprintCancer Biology